Works matching IS 20479158 AND DT 2025 AND VI 14 AND IP 1
Results: 6
Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives.
- Published in:
- Translational Neurodegeneration, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40035-025-00465-w
- By:
- Publication type:
- Article
Correction: Inflammasomes in neurodegenerative diseases.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington's disease.
- Published in:
- Translational Neurodegeneration, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40035-025-00466-9
- By:
- Publication type:
- Article
Correction: CD2AP deficiency aggravates Alzheimer's disease phenotypes and pathology through p38 MAPK activation.
- Published in:
- 2025
- By:
- Publication type:
- Correction Notice
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer's disease and correlates with tau pathology.
- Published in:
- Translational Neurodegeneration, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40035-024-00462-5
- By:
- Publication type:
- Article
Peripheral proteinopathy in neurodegenerative diseases.
- Published in:
- Translational Neurodegeneration, 2025, v. 14, n. 1, p. 1, doi. 10.1186/s40035-024-00461-6
- By:
- Publication type:
- Article